- Home
- DRUG vs DSGN Comparison
DRUG vs DSGN Comparison
Compare DRUG & DSGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DRUG
- DSGN
- Stock Information
- Founded
- DRUG 2019
- DSGN 2017
- Country
- DRUG United States
- DSGN United States
- Employees
- DRUG N/A
- DSGN N/A
- Industry
- DRUG Pharmaceuticals and Biotechnology
- DSGN Biotechnology: Pharmaceutical Preparations
- Sector
- DRUG Health Care
- DSGN Health Care
- Exchange
- DRUG Nasdaq
- DSGN Nasdaq
- Market Cap
- DRUG 199.7M
- DSGN 208.9M
- IPO Year
- DRUG N/A
- DSGN 2021
- Fundamental
- Price
- DRUG $25.41
- DSGN $4.00
- Analyst Decision
- DRUG Strong Buy
- DSGN Hold
- Analyst Count
- DRUG 7
- DSGN 1
- Target Price
- DRUG $83.25
- DSGN $4.00
- AVG Volume (30 Days)
- DRUG 60.0K
- DSGN 101.9K
- Earning Date
- DRUG 08-13-2025
- DSGN 08-04-2025
- Dividend Yield
- DRUG N/A
- DSGN N/A
- EPS Growth
- DRUG N/A
- DSGN N/A
- EPS
- DRUG N/A
- DSGN N/A
- Revenue
- DRUG N/A
- DSGN N/A
- Revenue This Year
- DRUG N/A
- DSGN N/A
- Revenue Next Year
- DRUG N/A
- DSGN N/A
- P/E Ratio
- DRUG N/A
- DSGN N/A
- Revenue Growth
- DRUG N/A
- DSGN N/A
- 52 Week Low
- DRUG $0.93
- DSGN $2.60
- 52 Week High
- DRUG $79.02
- DSGN $7.77
- Technical
- Relative Strength Index (RSI)
- DRUG 43.34
- DSGN 55.03
- Support Level
- DRUG $26.09
- DSGN $3.52
- Resistance Level
- DRUG $27.50
- DSGN $4.21
- Average True Range (ATR)
- DRUG 1.95
- DSGN 0.28
- MACD
- DRUG 0.12
- DSGN 0.03
- Stochastic Oscillator
- DRUG 44.62
- DSGN 77.27
About DRUG Bright Minds Biosciences Inc.
Bright Minds Biosciences Inc is focused on developing novel transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult to treat disorders such as resistant epilepsy, treatment resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.
About DSGN Design Therapeutics Inc.
Design Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the research and development of GeneTACTM molecules, which are a novel class of small-molecule gene-targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. The Company's product candidate is in Friedreich ataxia (FA), its second product candidate is in Fuchs endothelial corneal dystrophy (FECD), and it is also advancing its GeneTACTM program to address other serious nucleotide repeat-driven monogenic diseases.